Lymphoma Clinical Trials

Showing 1221-1240 of 2,926 trials

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

NCT01846390

This research is being done because it is not yet known what dose of romidepsin in combination with gemcitabine, dexamethasone, and cisplatin (GDP) can be given safely to patients with peripheral T-cell lymphoma, nor what type and severity of side effects will result from the combination of these treatments. This research is also being done because it is not clear if the addition of the new drug romidepsin to treatment with GDP can offer better results and longer survival.

Peripheral T-Cell LymphomaDiffuse Large B-Cell Lymphoma

Canadian Cancer Trials Group21 participantsStarted Oct 2013

Calgary, Alberta, Canada • Vancouver, British Columbia, Canada • Saint John, New Brunswick, Canada +3 more locations

COMPLETEDPhase 1

AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma

NCT00390117

RATIONALE: AT7519M may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AT7519M in treating patients with advanced or metastatic solid tumors or refractory non-Hodgkin's lymphoma.

LymphomaUnspecified Adult Solid Tumor, Protocol Specific

NCIC Clinical Trials Group34 participantsStarted Jan 2007

Hamilton, Ontario, Canada • Toronto, Ontario, Canada

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma

Related Searches

Bortezomib in Treating Patients With Mantle Cell Lymphoma

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Obinutuzumab in Chinese Real-world Patients With iNHL

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Construction of Diagnosis and Treatment System for Primary Vitreoretinal Lymphoma

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

FDG-PET/CT Imaging as Early Predictor of DP

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia